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Summary Apocrine differentiation in human breast cancers has been assessed using immunohistochemistry to
detect zinc a2 glycoprotein and the findings related to standard prognostic factors, disease free interval (DFI)
and survival in 145 women with early breast cancer. Breast tumour samples from women with a minimum
follow-up of 5 years were assessed. Routinely fixed and processed tissue was used throughout. Sixty-six (45%)
tumours did not stain with the antibody. Fifty-two (36%) exhibited positive apocrine staining while for 27
(19%) only a few cells were reactive. The presence of apocrine differentiation was unrelated to lymph node
status, menstrual status, tumour grade or size, oestrogen receptor (E2R) or progesterone receptor status.
However, patients whose tumours exhibited apocrine staining had a shorter disease-free interval (DFI)
(P = 0.03) and survival (P = 0.03). A Cox's multiple regression analysis of the data found that the presence of
staining added significantly (P = 0.047) to the predictive value of node status (P = 0.0001), menstrual status
(P = 0.0001), tumour size (P = 0.0026) and E2R status (P = 0.0014) for patient survival. The other seven
prognostic factors tested did not reach significance and were rejected from the model. Apocrine differentiation
in breast cancer appears to be an independent predictor of poor prognosis tumours.
The importance of apocrine differentiation in breast carcin-
omas is unknown because the incidence of apocrine change is
difficult to establish. No general agreement exists on the
criteria and extent of change required for categorisation. The
percentage of primary cancers displaying evidence of apo-
crine characteristics in different reported series has varied
between 0.3 and 57% (Azzopardi, 1979; Bonser et al., 1961;
Fisher et al., 1975; Haagensen, 1986). Haagensen has defined
apocrine carcinomas as tumours composed of large cells with
acidophilic cytoplasm, with evidence of cytoplasmic 'snouts'
in areas of tubular differentiation.
However, using immunohistochemical techniques employ-
ing antibodies to proteins found in apocrine secretions
(breast cyst proteins), more recent studies (Mazoujian et al.,
1983; Bundred et al., 1987a) have suggested that 40-50% of
unselected carcinomas exhibited apocrine differentiation, and
have demonstrated a good correlation between staining and
histological criteria.
Carcinomas showing apocrine differentiation have high Sr.
reductase activity, are capable of metabolising androgens and
possess androgen receptors, implying that they have a differ-
ent endocrine drive (Miller et al., 1988).
In the present study we have used an antibody to zinc a2
glycoprotein, a known marker of apocrine cell differentiation
(Bundred et al., 1987a), to examine the relationship between
expression of apocrine antigens and various prognostic fac-
tors and to determine whether the presence of apocrine
differentiation in tumours conferred any additional prognos-
tic information over the more standard prognostic factors.
Materials and methods
Patients
One hundred and forty-five women who presented to the
Breast Clinic of the University Department of Clinical
Surgery, Edinburgh, with primary operable breast cancer
were studied. Patients were treated by mastectomy, with
either axillary node sampling (n = 38), node sampling and
radiotherapy (n = 69) or axillary clearance (n = 38). All
patients were followed up clinically every 3 months for 18
months then every 6 months up to 5 years and once a year
thereafter. A minimum follow-up of 5 years or to a patient's
death was available for all the women. Forty-five women
received adjuvant therapy (Table I). The number of women
who received adjuvant therapy was equally matched between
groups.
Prognosticfactors
The following known prognostic factors were studied. Lymph
node status was obtained from the main histopathology
report and all patients were designated node positive or node
negative. The methods used to assess tumour grade, cel-
lularity, elastosis, oestrogen receptor and progesterone recep-
tor have been described in a previous publication (Hawkins
et al., 1987). Tumour histology was classified as either
'special type' or 'no special type'. Menstrual status was
classified by designating the patients as premenopausal (less
than 12 months since last menstrual period) or post-meno-
pausal (more than 12 months since last menstrual period,
hysterectomised-ovariectomised or hysterectomised and 50 or
more years of age) (Table I).
Immunohistochemistry
Zinc a2 glycoprotein antibody, a polyclonal rabbit antiserum,
was purchased from Behring Diagnostics UK. All tissues
were formalin fixed, paraffin embedded. The immunoperox-
idase technique has been described elsewhere (Bundred et al.,
1987a) and was a three stage peroxidase-antiperoxidase com-
plex method.
Zinc a2 glycoprotein antibody was applied diluted 1 in
1000 in phosphate buffered saline pH 7.4. The intermediate
step reagents were used at the following dilutions: Swine anti
rabbit immunoglobulin serum 1 in 30, rabbit peroxidase
antiperoxidase complex 1 in 50. These reagents were obtained
from DAKO Ltd. The diaminobenzidine hydrogen peroxide
reaction was employed to detect the peroxidase, with Mayer's
Haemalum as a nuclear counterstain. Controls were the use
of non-immune rabbit antiserum in place of the primary
antiserum. Previous absorption studies have been undertaken
(Bundred et al., 1987a).
The extent of staining was assessed in a semi-quantitative
method by two observers (R.A.W., N.J.B.) without prior
knowledge of the outcome of the patient. The number of
tumour cells staining was assessed and scored as: negative, no
staining, equivocal, 0-5% of total tumour cells stained; or
positive, 5-100% of total tumour cells stained (Figure 1).
The relationship of apocrine staining to other prognostic
factors was analysed by the test for trend, Spearman rank
correlation or x2 test as appropriate. Disease-free interval
and survival curves were calculated by the Kaplan-Meier
method. Cox's proportional hazards model was used to
assess the importance of each prognostic factor, both univar-
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Table I Relationship between apocrine stain and other factors
Apocrine stain
-ve + + ve
Node status
N - 35 (50%) 9 (13%) 26 (37%) Test for trend
N+ 31 (41%) 18 (24%) 26 (35%) P=0.7
Menstrual status
Pre 23 (52%) 4 ( 9%) 17 (39%) Test for trend
Post 43 (43%) 23 (23%) 35 (35%) P = 0.8
Tumour grade
I 7 (33%) 5 (24%) 9 (43%) Spearman rank correlation
II 31 (41%) 15 (20%) 29 (39%) P=0.06
III 28 (57%) 7 (14%) 14 (29%)
Tumour size
<2 cm 14 (45%) 4 (13%) 13 (42%) Spearman rank correlation
2-5cm 45 (45%) 21 (21%) 34 (34%) P=0.7
> 5 cm 7 (50%) 2 (14%) 14 (29%)
ER status
ER -ve 18 (51%) 5 (14%) 12 (34%) Test for trend
ER +ve 48 (44%) 22 (20%) 40 (36%) P = 0.5
PgR status
PgR -ve 33 (51%) 9 (14%) 23 (35%) Spearman rank correlation
PgR +/- 6 (67%) 1 (11%) 2 (22%) P=0.7
PgR + ve 27 (38%) 17 (24%) 27 (38%)
Initial treatment
Mx + sample 17 (45%) 3 ( 8%) 18 (47%) x2 test
Mx + sample + XRT 25 (36%) 16 (23%) 28 (41%) P= 0.01
Mx + clearance 24 (63%) 8 (21%) 6 (16%)
Adjuvant therapy
Tamoxifen 14 (50%) 8 (29%) 6 (21%) x2 test
Other 8 (47%) 2 (12%) 7 (41%) P= 0.4
None 44 (44%) 17 (17%) 39 (39%)
Total 66 (45%) 27 (19%) 52 (36%)
iantly and multivariantly. For univariant analysis the factors
were included in the model separately and significance levels
were obtained from the likelihood ratio. Test factors were
considered by adding them to the model in a step-wise
manner until no further significant improvement could be
made. Significance levels for all factors (included or excluded
from the model) were obtained from the likelihood ratio test.
Results
Sixty-six (45%) of the tumours did not exhibit any staining,
52 (36%) exhibited a positive reaction while 27 (19%) were
equivocal (Table II).
The relationship of apocrine staining to node status, men-
strual status, tumour grade or size, elastosis, oestrogen recep-
tor level and progesterone receptor status was examined and
no significant association between staining and any of these
parameters was found (Table I). There was a tendency for
patients with negatively staining tumours to have had exten-
sive axillary surgery but no significant differences were
assessed between the groups with regard to adjuvant therapy
(Table I).
Despite the excess of mastectomy and clearance in the
negative staining carcinomas, the initial treatment made no
difference to prognosis of the carcinomas as determined by
the univariate or multivariate analysis (Tables III, IV and V).
Analysis of disease-free interval (DFI) and survival curves
(Figure 2 and 3) using log rank Kaplan-Meier methods
demonstrates that tumours with apocrine differentiation
have a significantly reduced DFI (P = 0.03) and survival
(P = 0.05). Initial univariate analysis concentrated on the 118
women with positive or negative tumours, i.e. the equivocal
group was excluded. Univariate analysis found that eight of
the 12 prognostic factors tested proved to be significantly
predictive of survival (node status P<0.001; menstrual
status P = 0.0002; tumour grade P = 0.02; tumour size
P = 0.001; ER level P=0.002: progesterone receptor status
P = 0.004; elastosis P = 0.04 and apocrine stain P = 0.05).
Cox's multivariate regression analysis of the data from
these 118 women found that the presence of zinc o2 glyco-
protein added significantly (P = 0.006) to the predictive value
of node status (P = 0.0002), menstrual status (P = 0.0006),
tumour size (P = 0.0008) and ER status (P = 0.0004) for
patient survival. The other seven factors tested did not reach
significance and were rejected from the model. Likewise in a
similar analysis the presence of apocrine staining added signi-
ficantly (P = 0.016) to the predictive value of node status
(P = 0.004), menstrual status (P = 0.004), tumour size (P =
0.036) and oestrogen receptor status (P = 0.002) for patient
relapse-free interval.
To take account of the equivocally staining tumours a
second analysis was then carried out comparing 79 women
whose tumours showed any apocrine staining (i.e. positive
and equivocally staining tumours grouped together) com-
pared with the 66 women whose tumours did not stain. On
this analysis, the test for linear trend found that tumour
staining was associated with better grade tumours (P = 0.09).
No significant correlation between any of the other prognos-
tic factors was however found.
The second univariate analysis revealed that seven of the
12 prognostic factors (node status P = 0.0001; menstrual
status P = 0.0001; tumour grade P = 0.026; tumour size
P = 0.016; ER levels P= 0.005; PgR status P = 0.02 and
apocrine stain result P=0.03) (see Table III) were signi-
ficantly predictive of survival. A Cox's multivariate analysis
was then performed and factors added to the model until no
significant improvement in predicting the DFI and survival
could be made. Significant levels for exclusion from or in-
clusion into the model were calculated from the likelihood
ratio test (Tables IV and V). Apocrine stain result again
added significantly to the prognostic value of the model.
Other factors included in the model for survival were node
status, menstrual status, tumour size and ER level, for both
relapse free interval and survival. None of the other seven
factors was found to be significant in this form of analysis
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Table II Breast carcinomas stained for zinc a-2 glycoprotein
Number of Stain
Type ofcarcinoma cases + + -
Infiltrating ductal 133 51 24 58
Infiltrating lobular 7 1 1 5
Medullary 2 0 0 2
Mucoid 2 0 2 0
Papillary 1 0 0 1
Total 145 52 27 66
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Figure 1 Breast cancer sections x 200 stained with Zinc a2
Glycoprotein antibody showing (a) positive staining (b) equivocal
and (c) negative staining.
Table III Relationship of prognostic factors to disease-free interval
and survival by univariate analysis
Significance level
DFI Survival
Node status 0.0001 0.0001
Menstrual status 0.0035 0.0001
Tumour grade 0.042 0.026
Tumour size 0.013 0.016
ER level 0.0029 0.005
PgR status 0.11 0.021
Elastosis 0.3 (NS) 0.3 (NS)
Cellularity 0.6 (NS) 0.4 (NS)
Histology 0.5 (NS) 0.7 (NS)
Initial treatment 0.2 (NS) 0.2 (NS)
Adjuvant therapy 0.3 (NS) 0.4 (NS)
Apocrine stain 0.03 0.03
NS, not significant. Tumour size was as a continuous variable. Stain
was as present or absent.
Discussion
Krompecher first described apocrine breast carcinoma in
1916 but difficulties in categorising apocrine change have
made attempts at determining the clinical significance of such
differentiation impossible.
The diagnosis of apocrine carcinoma has rested on the
presence of large eosinophilic cells with basophilic nuclei and
bulbous apical snouts seen on haematoxylin and eosin
stained sections of breast cancer tissue (Azzopardi, 1979).
The subjectiveness of this diagnosis is illustrated by the varie-
ty of claims of the incidence of apocrine change in breast
cancer, ranging from 0.3 to 57%.
Haagensen (1986) has suggested that this sub-group of
breast carcinomas may arise from areas of gross cystic
disease with apocrine metaplasia. Zinc M2 glycoprotein forms
36% of the total protein content of apocrine sweat (Jirka,
1968) and is one of the major protein components of another
apocrine secretion, breast cyst fluid (Haagensen et al., 1979).
A previous study (Bundred et al., 1987a) has shown that
staining of tumour cells with an antiserum to zinc M2 glyco-
protein is a reliable immunohistochemical marker ofapocrine
differentiation in tumours. Workers using an antibody to
another cyst protein, GCDFP 15, have confirmed that
tumour apocrine differentiation can be objectively diagnosed
using immunohistochemistry and found an incidence of
50-80% of tumours exhibiting some degree of apocrine
change (Mazoujian et al., 1983; Miller et al., 1988; Le Dousal
et al., 1985). The incidence of 55% of tumours exhibiting
staining in this study is in broad agreement with these
figures.
Mossler et al. (1980), have claimed that apocrine car-
cinomas are deficient in oestrogen and progesterone receptors
but we have been unable to find any relationship with either
oestrogen or progesterone receptor status.
Two previous studies of tumour apocrine change using
antisera to GCDFP 15 have shown an association between
better differentiated tumours and immunohistochemically
determined GCDFP 15 expression (Le Dousal et al., 1985)
and high cytosol GCDFP 15 levels (Silva et al., 1982). We
were able to substantiate these findings, the better different-
iated carcinomas being less likely to be negative in com-
parision to the poorly differentiated tumours although the
association was a weak one.116 N.J. BUNDRED et al.
Table IV Relationship of prognostic factors to disease-free interval by multivariate
analysis (145 cases)
Coeff. s.e
Factor Groups (codes) (p) (P) P-valuea
Node status - ve (0) 1.433 0.283 <0.0001
+ ve (1)
Adjuvant therapy none (Al = 0, A2 = 0.) (Al) - 0.860 0.326 0.0001
tam (Al = 1, A2 = 0.) (A2) - 1.630 0.457
other (Al = 0, A2 = 1.)
Tumour size Not applicable 0.202 0.075 0.011
ER level <5 (0) - 0.672 0.264 0.014
5 5 (0)
Apocrine stain 0% (0) 0.247 0.121 0.038
>0% (2)
Elastosis 0 (El = 1, E2 =0) (E1) 0.758 0.350 0.035
I (El=1,E2=1) (E2) 0.031 0.297
2 (EI=0,E2=1)
0 = none, I = minimal, 2 = marked. aObtained from likelihood ratio test.
Table V Relationship ofprognostic factors to survival by multivariate
analysis (145 cases)
Groups Coeff. s.e.
Factor (codes) (i) (P) P-value a
Node status -ve (0) 1.058 0.289 0.0001
+ ve (1)
Menstrual status pre (1) - 1.322 0.386 0.0001
post (0)
Tumour size Not applicable 0.265 0.081 0.0026
ER level <5 (0) - 0.926 0.274 0.0014
>5 (1)
Apocrine stain 0% (0) 0.263 0.135 0.047
>0% (2)
aObtained from likelihood ratio test.
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Figure 2 Log rank curve of relapse-free interval (DFI) stratified
by apocrine stain status (P<0.05).
In many centres the only breast cancer tissue that is
available will be formalin fixed and paraffin embedded.
Various histological parameters can be assessed from haema-
toxylin and eosin stained sections of such material and some
of these, e.g. histological grade, can be of prognostic
significance (Elston et al., 1982). However, a major criticism
of these assessments is that they are subjective (Stenkvist et
al., 1979). The widespread use of immunohistochemistry has
allowed the determination of more objective assessments of
tumour behaviour. Immunohistochemical staining with the
monoclonal antibody NCRC II, which recognises compon-
ents of the milk fat globule membrane, can give prognostic
information (Ellis et al., 1985). However, the extent of stain-
ing relates to histological grade and oestrogen receptor
status. Other prognostic markers which can be defined by
immunohistochemistry such as epidermal growth factor
0)
0
._
0 0.
20
Co
E
I
1.0 Survival
0.8,
0.6
0.4
0.2
U0 14 28 42 56 70 84 98 112
Months
Nos at (-) 66 62 52 49 32 9
risk (+) (±) 79 72 59 48 32 9
Figure 3 Log rank curve of survival in 145 breast cancers
stratified by the presence or absence of apocrine staining:
positively staining tumours have a poorer survival (P<0.03).
receptor (Sainsbury et al., 1987) require fresh tumour tissue
for analysis. In this respect the immunohistochemical identi-
fication of apocrine change provides an independent prognos-
tic parameter which does not rely on a complex staining scale
assessment and can be applied to routinely fixed and pro-
cessed tissue.
In many centres the trend towards conservative surgery for
breast cancer (without determining node status) and the
absence of oestrogen receptor assay facilities has meant that
two of the most important prognostic factors are unavailable.
Apocrine staining may prove a useful objective prognostic
parameter in these patients and could be used to select
patients who require adjuvant therapy. Furthermore, the
recognition of apocrine differentiation in breast carcinomas
as a clinicopathological entity with a distinct natural history
may help therapeutically as such carcinomas are more likely
to express androgen receptors (Miller, 1988) and less likely to
respond to hormonal manipulation (Bundred et al., 1987b).
Why apocrine differentiation should be associated with
such a poor prognosis is not clear and must await further
investigation. Despite the excess of women undergoing
mastectomy and clearance whose tumours did not stain, the
initial treatment made no difference to the prognosis of the
carcinomas. This study shows that the identification of apo-
crine differentiation is of prognostic value and adds
significantly to the predictive ability of the other standard
prognostic factors.
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